Akorn

Ocular Therapeutix™ Announces Appointment of New Board Member

Retrieved on: 
Wednesday, July 12, 2023
Opus, University, Refractive surgery, Doctor of Philosophy, Emeritus, Stanford University, Eye, Himalayan Cataract Project, Research, ASCRS, RD, Ophthalmic, The Many Ghosts of Doctor Graves, Grave, Ophthalmology, OWL, Alcon, Brown University, ISCB Senior Scientist Award, Akorn, FFB, Cataract, Therapy, Society, Pharmaceutical industry, Management, Psychology

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.

Key Points: 
  • BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.
  • A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory.
  • She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

Prestige Consumer Healthcare Inc. Reports Record Fiscal Year 2023

Retrieved on: 
Thursday, May 4, 2023
International, Health care, Acquisition, PBH, Prestige Consumer Healthcare, OTC, Growth, Security (finance), EPS, Cough, NYSE, Year-ending, Sales, Video game, Pharmaceutical industry, Akorn, Cold

These attributes give us confidence in our business outlook for fiscal 2024 and our ability to drive shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Key Points: 
  • These attributes give us confidence in our business outlook for fiscal 2024 and our ability to drive shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
  • Fourth Fiscal Quarter Ended March 31, 2023
    Reported revenues in the fourth quarter of fiscal 2023 of $285.9 million increased 7.1% from $266.9 million in the fourth quarter of fiscal 2022.
  • The adjustment to net income in both fourth quarter fiscal 2022 and fiscal 2023 reflects a tax rate adjustment to account for discrete items.
  • Ron Lombardi, Chief Executive Officer, stated, “We are pleased to generate record sales and earnings in fiscal 2023 that built off our very strong fiscal 2022 performance.

Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown

Retrieved on: 
Wednesday, May 3, 2023
Online, Health, Completeness, File, Consumer, Akorn, Chapter Seven, Quality, II, ICA meat repackaging controversy, Internet, Animal, Patient, Knowledge, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Bankruptcy, Medical device, Dietary supplement

In connection with that filing, the company has ceased and shutdown all operations and terminated all its employees of all domestic US Sites.

Key Points: 
  • In connection with that filing, the company has ceased and shutdown all operations and terminated all its employees of all domestic US Sites.
  • The Akorn Trustee is initiating a voluntary recall of various within-expiry human and animal products as a result of the closures and discontinuation of the Quality activities of these marketed products.
  • The affected products are listed in Attachment I (human drugs) and II (animal drugs) of this release.
  • Products not included in the press are continuing to be monitored under a Quality Program and will remain on the market.

Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown

Retrieved on: 
Wednesday, April 26, 2023
Online, Health, Completeness, File, Consumer, Akorn, Chapter Seven, Quality, ICA meat repackaging controversy, Internet, Animal, Patient, Knowledge, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Bankruptcy, Medical device, Dietary supplement

In connection with that filing, the company has ceased and shutdown all operations and terminated all its employees of all domestic US Sites.

Key Points: 
  • In connection with that filing, the company has ceased and shutdown all operations and terminated all its employees of all domestic US Sites.
  • The Akorn Trustee is initiating a voluntary recall of various within-expiry human and animal products as a result of the closures and discontinuation of the Quality activities of these marketed products.
  • The affected products are listed in Attachment I (human drugs) and II (animal drugs) of this release.
  • Consumers with questions regarding this recall can contact Akorn at (800) 932-5676 during normal business hours (8am – 5pm CDT) Monday – Friday.

The Ritedose Corporation Begins production of Drug to Alleviate National Medication Shortage

Retrieved on: 
Tuesday, April 25, 2023
COPD, Akorn, Abbreviated New Drug Application, Asthma, Chastain, Inhalation, Chronic obstructive pulmonary disease, Hospital, Salbutamol, CGMP, Patient, COVID-19 pandemic, ANDA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BFS, Food, Pharmaceutical industry

COLUMBIA, S.C., April 25, 2023 /PRNewswire/ -- The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.

Key Points: 
  • In March, the U.S. Food and Drug Administration (FDA) announced a drastic downturn in the nation's supply of Albuterol Sulfate (0.5% Inhalation Solution).
  • "Major shifts in the market's ability to meet demand has driven our rapid response," said Jody Chastain, CEO of The Ritedose Corporation.
  • "We are all about patient safety and reliability—the U.S. can count on us to step-up and solve the drug shortage gap of Albuterol Sulfate."
  • For long-term supply chain continuity, Ritedose will be submitting an additional Abbreviated New Drug Application (ANDA) in other container sizes to meet supply demands.

Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer

Retrieved on: 
Wednesday, April 19, 2023
Actavis, Akorn, Global Operations, Health, Teva Pharmaceuticals, Patient, History, Engineering, Management

TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer.

Key Points: 
  • TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer.
  • Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations.
  • “Chris is a seasoned operations professional with strong and well-rounded manufacturing expertise, and a keen leadership acumen,” said Dave Stack, Chief Executive Officer and Chairman of Pacira.
  • Mr. Young has also held positions of increasing responsibility at Actavis/Alpharma/Purepac Pharmaceutical Co, Zenith Goldline Pharmaceuticals, and Copley Pharmaceutical, Inc.
    “I am pleased to join the Pacira management team, and excited to lead the manufacturing activities associated with the incredible assets in the Pacira product portfolio,” said Mr. Young.

End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure

Retrieved on: 
Wednesday, March 15, 2023
Other Manufacturing, Medical Supplies, Hospitals, Transport, Manufacturing, Practice Management, General Health, Pharmaceutical, Health, Logistics, Supply Chain Management, Oklahoma Hospital Association, Risk, Dimercaprol, Hyperparathyroidism, Supraventricular tachycardia, ASHP, Patient, EDSA, Calcitriol, Organic acid, Knowledge, Akorn, Physostigmine, East End Drugs, Bankruptcy, Adenosine, CHA, Anticholinergic, Mayo Clinic, Kidney, Pharmaceutical industry, Risk management, Medical device, Nursing, Vizient, Inc.

The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.

Key Points: 
  • The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
  • “Transparency regarding drug shortages is important to ensure patient care remains uninterrupted,” said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member.
  • Clinicians and providers, to exercise a stewardship mindset and review purchasing and formulary status to determine conservation and mitigation strategies.
  • “Advance knowledge of supply disruptions is part of the transparency that the End Drug Shortages Alliance has advocated for since forming.

Prestige Consumer Healthcare Inc. Reports Third Quarter Results

Retrieved on: 
Thursday, February 2, 2023
International, NYSE, PBH, Acquisition, OTC, Prestige Consumer Healthcare, Motion sickness, Health care, Investment, Growth, Eye, Cough, Video game, Security (finance), Health insurance, Pharmaceutical industry, Q3, Cold, Akorn

Reduced leverage ratio to 3.5x in Q3, enabled by strong profitability and cash flow

Key Points: 
  • Reduced leverage ratio to 3.5x in Q3, enabled by strong profitability and cash flow
    TARRYTOWN, N.Y., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third fiscal quarter ended December 31, 2022.
  • Our continued strong sales and profit growth drives our cash flow that continued to reduce our leverage ratio during the quarter and has us well positioned as we finish our fiscal year,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
  • Third Fiscal Quarter Ended December 31, 2022
    Reported revenues in the third quarter of fiscal 2023 of $275.5 million increased 0.4% from $274.5 million in the third quarter of fiscal 2022.
  • Reported net income for the third quarter of fiscal 2023 totaled $52.0 million, compared to the prior year third quarter’s net income of $50.2 million.

Maxwell Biosciences Names Two Biotech Leaders to Its Board of Directors

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Business administration, Virus, University of Tulsa, Biofilm, Therapy, Gynaecology, Allergan, General manager, Amneal Pharmaceuticals, Cardiology, Fungus, Tissue, AbbVie, Board, Perrigo, Executive, FDA, McKinley, Psychology, University, Nature, Kate, Commercial Operating System (COS), Urology, Organization, Business, Bacteria, Princeton University, Record, Wharton School of the University of Pennsylvania, Immune system, Laboratory, Board of directors, R, Immunotherapy, Chief executive officer, Patient, Vaccine, Management, Actavis, Science, Akorn, Dendreon, Medication, Marketing

The appointments add experienced pharmaceutical industry CEOs with extensive commercialization, distribution and successful market access expertise to Maxwells board.

Key Points: 
  • The appointments add experienced pharmaceutical industry CEOs with extensive commercialization, distribution and successful market access expertise to Maxwells board.
  • I am pleased to welcome Kate and Doug to Maxwells Board of Directors, said Maxwell Biosciences Chairman and CEO Joshua McClure.
  • Kate McKinley has successfully executed regulatory and commercial strategies in cell therapy and small molecule oncology throughout her more than 20-year career in biotech.
  • To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com , or follow us on Twitter and LinkedIn .

Europe Artificial Tears (Cellulose, Glycerin, Oil-Based Emulsion, Polyethylene Glycol, Propylene Glycol) Market Research Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Pharmaceutical, Health, Optical, Man, R, Akorn, Prevalence, Government, Sex, Tears, Irritation, Lists of diseases, Bausch, Joint Medical Service (Germany), Ageing, Woman, Population, Dry eye syndrome, Allergan, Inc., Incidence, Cosmetics, Marketing

The "Europe Artificial Tears Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Artificial Tears Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Although, innovations such as preservative-free artificial tears in artificial tears could be perceived as a major opportunity for the players engaged in the market.
  • Based on type, the market is segmented into cellulose-derived tears, glycerin-derived tears, oil-based emulsion tears, polyethylene glycol- & propylene glycol-based tears.
  • Insights about market determinants that are stimulating the European artificial tears market.